<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192230</url>
  </required_header>
  <id_info>
    <org_study_id>EndoDocNSCLC</org_study_id>
    <nct_id>NCT01192230</nct_id>
  </id_info>
  <brief_title>Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>A Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy and safety of endostatin combined with
      Docetaxel in advanced Non-Small-Cell Lung Carcinoma (NSCLC) patients failure to first-line or
      second-line chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>six weeks</time_frame>
    <description>EORTC QLQ-C30(v3.0)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostatins</intervention_name>
    <description>7.5mg/m2 qd *14d,q3w</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2 D1, q3w,4-6cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were diagnosed by the histologic, cytologic diagnosis of IIIB (malignant
             hydrothorax or hydropericardium) or IV non-small cell lung cancer

          -  ≥ 18 years old

          -  patients who have received more than one regimen of platinum-based chemotherapy;
             patients who have received EGFR monoclonal treatment could also be enrolled

          -  At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and can
             be measured by imaging tools

          -  have an interval of more than 4 weeks from the last chemo- or radio-therapy; 2 weeks
             from the last targeted therapy

          -  ECOG 0-2

          -  Expected life time longer than 3 months

          -  Normal laboratory values:

               -  leucocyte≥ 4×109/L

               -  neutrophil≥ 1.5×109/L

               -  platelet≥90×109/L

               -  Hemoglobin≥ 9g/L

               -  ALT and AST ≤3×ULN (≤5×ULN if liver metastasis)

               -  serum creatinine&lt;1.5 mg/dl

               -  bilirubin &lt;1.5×ULN

          -  No allergy to biological drug

          -  Sign the consent forms

        Exclusion Criteria:

          -  Patients who have previously received Docetaxel or anti-VEGF inhibitors

          -  Severe symptomatic heart disease

          -  Female patients during their pregnant and lactation period, or patients without
             contraception

          -  Severe uncontrolled infection

          -  Uncontrolled neurologic or psychiatric disease; Uncontrolled primary or metastatic
             brain tumor

          -  Patients with other malignant tumor,except for basal cell carcinoma,squamous cell
             carcinoma and carcinoma in situ

          -  Patients have accepted other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Chang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University affiliated cancer hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianhua Chang, MD,PhD</last_name>
    <phone>13916619284</phone>
    <email>changjianhua@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Chang, MD,PhD</last_name>
      <phone>13916619284</phone>
      <email>changjianhua@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Base for drug clinical trials, Fudan University Cancer Hospital</name_title>
    <organization>Department of Medical Oncology,Fudan University Cancer Hospital</organization>
  </responsible_party>
  <keyword>Objective response rate</keyword>
  <keyword>Disease control rate</keyword>
  <keyword>Disease free survival</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Quality of Live</keyword>
  <keyword>Nonsmall cell lung cancer</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

